High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis

Journal of Hepatology

Volumn 65, Issue 5, 2016, Pages 1070-1071

  Cardoso, Helder ^a   Vale, Ana Maria ^a   Rodrigues, Susana ^a   Gonçalves, Regina ^a   Albuquerque, Andreia ^a   Pereira, Pedro ^a   Lopes, Susana ^a   Silva, Marco ^a   Andrade, Patrícia ^a   Morais, Rui ^a   Coelho, Rosa ^a   Macedo, Guilherme ^a  

^a University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR; SOFOSBUVIR; INTERFERON;

ANTIVIRAL THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FOLLOW UP; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; CHRONIC HEPATITIS C; INCIDENCE; LIVER TUMOR; RISK FACTOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84991502867     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.027     Document Type: Letter

References (6)

1. [1] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
2. [2] Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.P., Giuily, N., Castelnau, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52 (2010), 652–657.
3. [3] El-Serag, H.B., Kanwal, F., Richardson, P., Kramer, J., Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection. Hepatology, 2016, 10.1002/hep.28535.
4. [4] European Organisation for Research and Treatment of Cancer, European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
5. [5] Lok, A.S., Seeff, L.B., Morgan, T.R., di Bisceglie, A.M., Sterling, R.K., Curto, T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009), 138–148.
6. [6] Rodrigues-Pinto, E., Cardoso, H., Coelho, R., Andrade, P., Macedo, G., Higher aspartate aminotransferase platelet ratio index predicts early significant liver-related events in hepatitis C genotype 1 chronic liver disease. Eur J Gastroenterol Hepatol 27 (2015), 361–362.